Results 61 to 70 of about 337 (145)

A Prognostic Stratification Model for Ovarian Cancer Integrating the Tumor‐Associated Macrophages/Programmed Death‐Ligand 1 Axis

Organ Medicine, Volume 3, Issue 3, Page 148-156, September 2026.
Tumor‐associated macrophages (TAMs) drive ovarian cancer (OC) progression and immune escape mainly via programmed death‐ligand 1 (PD‐L1) upregulation. This study aimed to construct a risk stratification model integrating these two immune biomarkers for OC precision prognosis.
Li Liu, Chenya Zhuo, Tingting Zhao, Qiongshan Liu, Yun Liu, Jingran Du, Dandan Yan, Qiuxiao Tan, Hui Fei, Xiaohui Tian, Mengxiong Li   +10 more
wiley   +1 more source

Evaluation of patient/caregiver and healthcare provider knowledge, attitudes and behavior for safety and use of pexidartinib

Journal of Comparative Effectiveness Research, 2021
Aim: Pexidartinib was approved for the treatment of tenosynovial giant cell tumors with a required Risk Evaluation and Mitigation Strategy (REMS) to ensure its safe use. As required by the REMS, a survey was conducted to document the knowledge, attitudes and behavior (KAB) of patients/caregivers and healthcare providers (HCPs ...
Maribel Salas, Michele Julian, Youngsook Choi, Zahid Islam, Mackenzie Henderson, Annette Stemhagen, Natalie O'Donnell, Nora Tu   +7 more
openaire   +2 more sources

A phase 1/2 study of the oral FLT3 inhibitor pexidartinib in relapsed/refractory FLT3-ITD-mutant acute myeloid leukemia. [PDF]

, 2020
FMS-like tyrosine kinase 3 (FLT3) tyrosine kinase inhibitors (TKIs) have activity in acute myeloid leukemia (AML) patients with FLT3 internal tandem duplication (ITD) mutations, but efficacy is limited by resistance-conferring kinase domain mutations ...
Roboz, Gail J, Levis, Mark J, Pagel, John M, Severson, Paul L, Hsu, Henry H, Bollag, Gideon, West, Brian L, Le, Mai H, Kayser, Sabine, Lam, Bao, Zhang, Chao, Perl, Alexander E, Wang, Eunice S, Smith, Catherine C, Frankfurt, Olga, Stone, Richard M   +15 more
core   +2 more sources

Polyoxazoline‐Based Nanovaccine Synergizes with Tumor‐Associated Macrophage Targeting and Anti‐PD‐1 Immunotherapy against Solid Tumors

Advanced Science, 2023
Immune checkpoint blockade reaches remarkable clinical responses. However, even in the most favorable cases, half of these patients do not benefit from these therapies in the long term.
Ana I. Matos, Carina Peres, Barbara Carreira, Liane I. F. Moura, Rita C. Acúrcio, Theresa Vogel, Erik Wegener, Filipa Ribeiro, Marta B. Afonso, Fábio M. F. Santos, Águeda Martínez‐Barriocanal, Diego Arango, Ana S. Viana, Pedro M. P. Góis, Liana C. Silva, Cecília M. P. Rodrigues, Luis Graca, Rainer Jordan, Ronit Satchi‐Fainaro, Helena F. Florindo   +19 more
doaj   +1 more source

Histiocytosis development and clinical variation through the lens of genomics

The Journal of Pathology, Volume 270, Issue 1, Page 23-39, September 2026.
Abstract Histiocytic neoplasms are rare haematologic diseases characterised by clonal expansions of cells with a monocyte, macrophage or dendritic cell phenotype. Their clinical manifestations are diverse, ranging from indolent lesions to aggressive systemic disease.
Paul G Kemps, Astrid GS van Halteren, Tom van Wezel, Pancras CW Hogendoorn   +3 more
wiley   +1 more source

Fragment-Based Drug Discovery as a strategy to develop drugs on new therapeutic targets: the case of Pexidartinib. [PDF]

, 2022
openIl Fragment-Based Drug Discovery (FBDD) è un metodo innovativo grazie al quale, partendo da piccoli frammenti che si legano debolmente al bersaglio, è possibile ottenere una molecola che ha un’affinità di legame con il bersaglio molto maggiore dei
CHIAPPETTA, GIACOMO
core  

Oxygen–Glucose Deprivation Increases NR4A1 Expression and Promotes Its Extranuclear Translocation in Mouse Astrocytes

Brain Sciences
Hypoxic–ischemic brain injury induces metabolic dysfunction that ultimately leads to neuronal cell death. Astrocytes, a type of glial cell, play a key role in brain metabolism; however, their response to hypoxic–ischemic brain injury is not fully ...
Kengo Moriyama, Asako Horino, Kuniko Kohyama, Yasumasa Nishito, Tomohiro Morio, Hiroshi Sakuma   +5 more
doaj   +1 more source

Reduced colony‐stimulating factor 1 receptor expression in myeloid cells has limited impact on chronic lymphocytic leukaemia progression

British Journal of Haematology, Volume 209, Issue 3, Page 939-952, September 2026.
Summary Targeting the colony‐stimulating factor 1 receptor (CSF1R) to remove tumour‐associated macrophages is being explored as cancer therapy. This strategy may be relevant for chronic lymphocytic leukaemia (CLL), which strongly depends on support from myeloid cells.
Natascha Rosen, Guillermo Rodriguez‐Real, Alexander F. vom Stein, Luca D. Schreurs, Trong‐Hieu Nguyen, Viktoria Kohlhas, Thanh‐Tung Truong, Maximilian Koch, Sebastian Reinartz, Sumiya Iqbal, Shaista Ilyas, Sanjay Mathur, Nina Reinart, Phuong‐Hien Nguyen, Michael Hallek   +14 more
wiley   +1 more source

Understanding Postmarketing Requirements and Commitments for CYP3A‐Mediated Drug–Drug Interactions: An Analysis of FDA‐Approved Drugs From 2015 to 2024

Clinical and Translational Science, Volume 19, Issue 9, September 2026.
ABSTRACT Addressing knowledge gaps at drug approval through drug–drug interaction (DDI)‐related postmarketing requirements (PMRs) and commitments (PMCs) is essential for safe and effective use. This analysis reviewed CYP3A‐related PMRs and PMCs, the most evaluated enzyme in postmarketing studies, to characterize their scope.
Jingjing Yu, Ichiko Petrie, Sophie Argon, Katie Owens, Isabelle Ragueneau‐Majlessi   +4 more
wiley   +1 more source

Design and Synthesis of Pyridine-Based Pyrrolo[2,3-d]pyrimidine Analogs as CSF1R Inhibitors: Molecular Hybridization and Scaffold Hopping Approach

Pharmaceuticals
Background/Objectives: Colony stimulating factor 1 receptor kinase (CSF1R) is a well-validated molecular target in drug discovery for various reasons.
Srinivasulu Cherukupalli, Carsten Degenhart, Peter Habenberger, Anke Unger, Jan Eickhoff, Bård Helge Hoff, Eirik Sundby   +6 more
doaj   +1 more source